Replication defective vectors derived from simple retroviruses or the more complex genomes of lentiviruses continue to offer the advantages of long-term expression, cell and tissue specific tropism, and large packaging capacity for the delivery of therapeutic genes. The occurrence of adverse events caused by insertional mutagenesis in three patients in a gene therapy trial for X-linked SCID emphasizes the potential for problems in translating this approach to the clinic. Several genome-wide studies of retroviral integration are now providing novel insights into the integration site preferences of different vector classes. We review recent developments in vector design, integration, biosafety, and production.
In brief Progress
Cis-elements within retroviral expression constructs increase vector titer and/or gene transfer efficiency. Several approaches for expressing multiple genes in a single vector are available. The number of envelope pseudotypes available for cell-and tissue-specific tropism continues to expand. Inducible and tissue-specific promoters are available for retro/lentiviral vectors. Recent vector modifications address transcriptional silencing. The risks for insertional mutagenesis are beginning to be evaluated. Genome-wide mapping of retro/lentiviral vector insertion sites are defining differences among vector classes. Vector safety modifications including self-inactivation (SIN), chromosomal insulators, and tissue-specific promoters continue to be validated and refined. Methods for achieving high titer vector utilize stable vector producing cell lines or transient vector production systems. Several different procedures for vector production, vector purification, and replication competent retrovirus (RCR) tests are being explored. The first clinical trial with lentiviral vector (HIV-1 based vector for anti-HIV therapy) has begun.
Prospects
Identification of cis-elements will define boundaries between expression cassettes and the genome, enhance vector safety and expression. Large-scale mapping studies have implications for goal of engineering vectors with targeted integration properties. Assays for detection of replication competent lentivirus (RCL), including appropriate positive control will be refined to further increase lentiviral vector safety. The establishment of large-scale production of retroviral vectors in bioreactors with higher efficiency is anticipated. Progress in the development of serum-free media for clinical grade retroviral vector production will continue. The first clinical trial with a lentiviral vector is underway with others anticipated.
Cis-elements within retroviral expression constructs increase vector titer and/or gene transfer efficiency
Considerable effort has been devoted to deleting or altering native sequence in retroviral and lentiviral vector constructs, to prevent the generation of replication competent retroviruses (RCR) typically caused by homologous recombination (reviewed in Delenda 1 ). Ciselements within the transfer vector are minimized and necessary trans-elements are supplied from packaging and envelope helper constructs (Figure 1 ). The packaging constructs are generated by replacing the 5 0 and 3 0 long terminal repeat (LTR) with a heterologous promoter and a heterologous polyadenylation signal, respectively. The packaging signal and unnecessary accessory genes (such as HIV-1 vif, vpr, vpu, and nef) are often deleted from packaging constructs.
A minimal transgene expression cassette contains the LTRs, packaging signal, a heterologous promoter and transgene of interest. However, to increase gene transfer efficiency, additional cis-acting regulatory sequences are routinely incorporated into retroviral vector backbones. The central polypurine tract (cPPT) enhances HIV vector efficiency by facilitating nuclear translocation of preintegration complexes. The benefit of incorporating a lentiviral cPPT has been demonstrated for HIV-1, SIV, and EIAV 2 (reviewed in Logan et al )
. In addition, incorporation of the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) increases the levels of transgene expression from retroviral vectors by increasing RNA stability. Combining the WPRE with the untranslated regions of the rat tau, the tyrosine hydroxylase, and the human Alzheimer amyloid precursor protein resulted in further additive enhancement of transgene expression. 4 The WPRE may exhibit promoter activity and the potential to express a 60 amino-acid woodchuck hepatitis virus (WHV) X protein-derived protein. The WHV X protein has been implicated in the generation of liver cancers; however, there is no direct evidence that the N-terminal fragment used as a cis element in vectors is oncogenic. 5 Several approaches for expressing multiple genes for a single vector are available Expressing more than a single transgene from a viral vector may be required for effective therapy or experimental design. This is most commonly achieved using bicistronic expression cassettes with an internal ribosome entry site (IRES). 6 An important use of multiple transgene expression systems is the enrichment of a transduced cell population expressing genes conferring drug-resistance by in vitro or in vivo selection. The human alkylating drug resistance mutant O(6)-ethylguanine DNA methyltransferase has been utilized in vitro to this end. 7, 8 Other gene transfer applications may necessitate expression of more than two genes. Lentiviral vectors are suitable for multiple expression cassettes due to their large packaging capacity. The capacity is generally considered to be 8-10 kb; however, unlike AAV or adenovirus, the limit is not a strict cutoff, rather, the packaging efficiency is inversely proportional to the insert size. Three different catecholaminergic synthetic enzymes were delivered from a single EIAV-based vector for a Parkinson's disease application. 6 In addition, a modular, tricistronic HIV-1 transfer vector was developed for coexpression of up to three transgenes. 9 As an alternative to expressing two transcripts from two internal promoters, 10 Figure 1 Minimal HIV vector plasmid (1) consisting of the CMV/HIV LTR hybrid promoter followed by the packaging signal (C), the rev-binding element RRE for cytoplasmic export of the RNA, the transgene expression cassette consisting of internal promoter(s) and transgene(s), and the 3 0 self-inactivating (SIN) LTR. All genes coding for enzymatic or structural HIV proteins have been removed. Together with the HIV vector plasmid (1), the HIV packaging plasmid (2), HIV rev (3), and an envelope expressing plasmid (4) are needed for HIV vector production. The number of envelope pseudotypes available for cell-and tissue-specific tropism continues to expand
In retroviral packaging constructs, the retrovirus' native envelope is typically replaced with a helper plasmid expressing heterologous envelope glycoproteins. This process, termed pseudotyping, can greatly modify the cell and host range tropism of the vector (reviewed in Sanders 16 ). The vesicular stomatitis virus glycoprotein (VSV-G) has been extensively used to this end. The compatibility of retro-and lentiviral vectors with a broad range of viral envelope glycoproteins is quite remarkable. Many heterologous viral envelope glycoproteins have successfully been used to pseudotype retroviral and lentiviral particles including those from lyssaviruses, 17 arenaviruses, 18 hepadnaviridae, 19 flaviviridae, 20 paramyxoviridae, 21 baculovirus, 22 filoviruses, 23 and alphaviruses. 24, 25 Often, high titer production can be a problem after pseudotyping and the heterologous viral glycoproteins must be modified to achieve efficient pseudotyping or appropriate cell targeting. Truncation of the intracellular domain is an effective technique to improve pseudotyping with an heterologous envelope. In addition, Jeffers and co-workers 26, 27 greatly improved the pseudotyping efficiency of Moloney murine leukemia virus (MuLV) with the Ebola envelope GP by deleting a heavily O-glycosylated region of the extracellular domain. Assembly of retroviral particles requires interactions of the pseudotyping glycoprotein's cytoplasmic tail with the virion core. Recently, Merten and co-workers [28] [29] [30] used a directed evolution approach to generate novel Cterminal tails for the gibbon ape leukemia virus (GALV) envelope that were compatible with HIV vectors. Briefly, Merten and co-workers screened a GALV env library with variations at three critical amino-acid residues for the ability mediate HIV-1 vector gene transfer.
Inducible and tissue-specific promoters are available for retro/lentiviral vectors For many human gene transfer applications, the potential to regulate transgene expression is appealing. A commonly used inducible promoter is the tetracycline inducible (tet-on) system. At some level, all regulated promoters are subject to unregulated expression. Recently, a codon-optimized tetracycline trans-activator has reduced the 'leakiness' in different cell types, 31, 32 and the use of ecdysone regulated promoters with MuLV and HIV vectors has been described. 33, 34 Long-term tissue or cell specific expression can be facilitated by the choice of promoters. For example, liver expression with the human phosphoglycerate kinase (hPGK) or albumin promoters offer advantages over the commonly used cytomegalovirus (CMV) promoter. 35 
Recent vector modifications address transcriptional silencing
Lentiviral genomes contain fewer CpG dinucleotides than onco-retroviral vectors. This may contribute to the experimental observation that lentiviral vectors are more resistant to silencing. 36 De novo cytosine methylation of CpG dinucleotides contributes to integrated retroviral vector silencing by inducing histone deacetylation and chromatin condensation.
Three cis-elements are under investigation for their ability to avoid transgene silencing: (1) locus control regions (LCRs); (2) chromatin insulators; and (3) scaffold/matrix attachment regions (S/MARs). DNase I hypersensitive sites upstream of the b-globin cluster, termed b-LCR, are regions of highly accessible chromatin. In situ, the b-LCR is 20 kb long; however, segments of a few hundred bps have been reported to confer copy number-dependent and position-independent antisilencing activity, and have been successfully used in HIV-1 vectors in vitro 37 and in vivo. 38 Chromatin insulators protect gene expression from neighboring enhancers or silencers and have been identified from a variety of species including: the scs and scs' elements, which flank the hsp70 genes in Drosophila melanogaster, BEAD-1 from the human T-cell receptor gene locus, and the intergenic spacer of the ribosomal RNA genes of Xenopus. However, perhaps the best characterized chromatin insulator to date is the HS4 core from the chicken b-globin LCR 39, 40 and reviewed in West et al. 41 The cHS4 insulator facilitated persistent HIV-1 vector expression in human hematopoietic stem cells. 42 In contrast, in the context of MuLV vectors neither scs, BEAD-1 or HS4 successfully shielded an internal promoter from the repressive effect of the silencer. S/MARs are structural DNA sequences necessary for the attachment of individual chromatin loops to protein complexes and potentially confer insulating properties. The addition of S/MAR elements to an HIV-1 vector significantly increased the liver and hepatocyte transduction efficiency 43 and transgene expression in human hematopoietic stem cells. 42, 44 Investigation of lentiviral silencing and issues of the tissue-specificity of silencing remain active areas of study.
The risks for insertional mutagenesis are beginning to be evaluated While retroviral vectors offer a means to permanently correct genetic diseases by stably expressing a transgene, all current integrating gene transfer vectors carry a finite risk of insertional mutagenesis. The theoretical possibility of such an outcome has long been recognized and formally shown in mouse studies. 45 Since retroviral integration events are mono-allelic, only dominant effects should be harmful. However, the occurrence of leukemia in three of 11 children with X-linked SCID following ex vivo gene transfer of the common gamma chain cDNA to CD34+ hematopoietic stem cells with an MuLV vector emphasizes the potential for adverse events in the clinic. 46, 47 Molecular analysis of the three affected patient's cells from the X-SCID gene therapy trial suggests that the problems that occurred are likely disease-specific, a result of the transgene expressed, the selective advantage gained by the transduced cells, the Development of improved lentiviral and retroviral vectors PL Sinn et al patients' underlying immunodeficiency, and the specific MuLV vector construct used. 47 Results from a second X-SCID ex vivo GALV pseudotyped MuLV gene therapy trial were recently reported in four patients and no adverse events were reported in followup of up to 29 months. 48 Importantly, more than 200 unique insertion sites were mapped and none occurred near the LMO2 locus. 48 Methods for evaluating the sites of vector integration include LAM PCR 48 and adapter-ligated nested PCR. 49 In contrast to findings in the first X-linked SCID trial, there have been no reports of insertional mutagenesis in patients with adenosine deaminase deficiency (ADA)-SCID treated with MuLV vector gene transfer to hematopoietic stem cells. 50, 51 Retroviral marking studies in murine and human hematopoietic stem cells with vectors expressing a truncated form of the p75 low-affinity nerve growth factor receptor similarly found no evidence of tumorogenesis. 52 Furthermore, a long-term follow-up (1-7 years) of retroviral gene transfer to hematopoietic stem cells in dogs and non-human primates reported no evidence for clonal expansion or insertional mutagenesis. 53 Thus, the risks of insertional mutagenesis may depend on the vector system, the targeted cell types, the site of integration, and the transgene expressed.
Genome-wide mapping of retro/lentiviral vector insertion sites are defining differences among vector classes Studies of the integration preferences of onco-retroviruses and primate and nonprimate lentiviruses are providing new insights into the biology of retroviral integration and the risks and advantages of different vector systems. 49, [54] [55] [56] The availability of the human genome sequence has facilitated several large-scale mapping studies of retroviral integration in human cells. Bushman and co-workers 49, 55 reported that HIV-1 integration occurred along the length of transcriptionally active genes in three cell types. Several HIV-1 integration hotspots were identified, including a 2.5 kb region containing 1% of the integration events. In contrast, MuLV vector integration predominantly occurred near transcription start regions and CpG islands in HeLa cells. 54 Unlike either HIV or MuLV vectors, avian sarcoma leukosis virus (ASLV) exhibited a distinct pattern of integration in 293 cells, demonstrating little bias towards integration in transcriptionally active genes and no preference for integration near transcription start sites. 55, 56 Thus, significant differences exist among retroviral vectors, lending support to the idea that both vector and host factors are important determinants of vector integration sites. In addition, integration may be cell-type specific and different in dividing and nondividing cells. Therefore, some of the risks of using retroviral vectors in gene therapy applications may be vector-dependent.
Understanding the sites of vector integration has important implications for clinical applications. Approximately 17% of MuLV-based vector integration occurred in and around transcriptional start regions and another 17% of integration occurred within 1 kb of CpG islands. 54 An integration preference near promoters may increase the risk of oncogenesis for at least three reasons: (1) the vector may directly act upon a nearby gene enhancer or promoter and influence gene expression; (2) the vector LTR promoter itself may give rise to a full-length, functional gene transcript; and (3) the presence of the vector DNA may cause changes to the local chromatin structure in a gene's regulatory region that influences gene expression. Lentiviral vectors studied to date integrate across the entire transcribed region of genes with no preference for regions near the transcriptional start. Transgene integration in introns is unlikely to disturb gene function. Additionally, in comparison to MuLV vectors, the chances of promoter activation by integrated lentiviral vectors may be lower. Therefore, lentiviral vectors may be less prone to insertional mutagenesis, compared to their oncoretroviral counterparts. 57 Vector safety modifications including selfinactivation (SIN), chromosomal insulators, and tissue-specific promoters continue to be validated and refined Several strategies can be implemented to decrease the risks of insertional mutagenesis. SIN vector systems, in which the U3 region of the viral LTR is deleted, have been developed and are currently used in a variety of lentiviral gene transfer experiments. SIN vectors are expected to improve safety profiles by eliminating the viral LTR enhancer/promoter activity. 58 Additional strategies including the incorporation of chromosomal insulators into the vector construct and the use of tissue and cell specific promoters were described above.
Ultimately, it would be desirable to modify the retroviral vectors to control where integration occurs. Theoretically, this could be accomplished through the insertion of a specific DNA binding domain into the viral integrase or other associated proteins to tether the preintegration complex to safe genomic DNA targets. Several efforts have been made in this direction, although the holy grail of safe and site-specific integration has not yet been achieved. 59 A fusion of HIV integrase to the zinc-finger protein zif268 directed increased integration near zif268 recognition sites in vitro. Chow et al demonstrated that fusion proteins incorporating HIV IN fused to the E2C zinc-finger protein maintain IN activity and direct integration of viral DNA into specific sites in cell free assays. 60 Voytas and co-workers 61 recently substituted the IN-targeting domain of the retrotransposon Ty5 with different peptide motifs and successfully retargeted integration in yeast. This novel finding in a eukaryotic cell raises the prospect that such a tethering strategy might be successfully employed for retroviral vectors. 62, 63 Interestingly, the cellular protein Ledgf/p75 was identified as such a candidate tethering protein for HIV and FIV lentiviruses. 64 
Methods for achieving high titer vector utilize stable vector producing cell lines (VCL) or transient vector production systems Vector producing cell lines
Previous work with VCL has shown that desirable features such as high titer, safety, and scalability depend ). Typically, oncoretroviral MuLV vectors are produced by VCLs constitutively expressing all three vector components (transfer vector, packaging, envelope) whereas lentiviral vectors are produced either transiently or, to a lesser degree, by inducible VCLs. Toxicity of lentiviral enzymes, HIV accessory proteins, and the fusogenic VSV-G prohibit constitutive expression. For clinical applications, VCL-produced vector is preferred over transiently generated material since in depth molecular characterization of the producer line ensures a higher level of safety and less complex vector production reduces batchto-batch variation.
While VCL production methods are well established, further refinements facilitating the identification of high titer packaging cells and VCLs are ongoing. For example, Green and Rasko 66 developed a 96-well format, highthroughput packaging cell screening method using quantification of fluorescent reporters and Loew et al 67 optimized VCL screening through the reversible integration of lox-P-flanked GFP in the provector, allowing expedient detection of high titer clones while Cre recombinase-mediated excision of GFP generates marker-less vectors desirable for clinical applications.
To increase vector safety, the use of human parent cells and viral sequence reduction continues. More recently, the driving forces behind construct minimalization are biosafety concerns with HIV-based lentiviral vectors. Examples include deletion of the rev sequence while providing Rev-Tat or Rev-Pep1 fusion proteins during vector production with little compromise in titer. 68 To reduce mobilization of lentiviral vectors by wild-type virus, an SIV vector mutated in the primer binding site to prevent reverse transcription was generated by providing artificial tRNA during vector production. 69, 70 Adding to the arsenal of previously described inducible lentiviral vector production systems 71 that suffer from titer loss and unregulated basal activity, Kuate et al 72 offer a minimal SIV packaging cell line with pronasteroneinducible vector components. Surprisingly, a noninducible HIV packaging construct coding for gag, pol, tat and rev was constitutively expressed in three human cell lines (HeLa, 293T, HT-1080) when introduced via transduction but was less successful when introduced by standard transfection. 73 The resulting 'STAR' VCLs generated high titer HIV-based lentiviral vectors (410 7 TU/ml) for at least 3 months. 71 Why transduction and not transfection of the HIV packaging component facilitates stable expression remains unclear.
Transient vector production and hybrid vector systems
To avoid the tedious process of VCL production all together, transient production is a commonly used alternative, especially for lentiviral vectors. Transient production in human 293T cells is fast and allows the use of toxic, fusogenic, or cytostatic vector or transgene. Transient production has been further refined by optimizing various parameters such as the amount and ratio of plasmid DNA, 17, 74, 75 cell density and growth phase, time of harvest, 76 calcium phosphate buffer conditions, and the use of sodium butyrate. 17, 74 Whereas most transfection protocols rely on CaPO 4 precipitation, 17 ,77 the use of activated dendrimers (SuperFect) 76 or cationic lipids provides more reproducible vector batches and less DNA is needed. For advantages and disadvantages of vector production using VCLs or transient procedures, see Table 1 .
Another strategy is the development of hybrid vectors for in vitro or in vivo vector production. Combining desirable adenoviral (Ad) characteristics such as high titer, targeting, and transduction of nondividing cells with the potentially lifelong transgene expression afforded by retroviral vectors, is particularly attractive. [78] [79] [80] [81] [82] Progress includes first reports of high-capacity Ad vectors delivering either replication-competent retrovirus, 79, 83 tetracycline-inducible lentiviral vector 81 or foamy vector. 82 High capacity Ad vectors eliminate the need for multiple first generation Ad vectors. Reports of additional hybrid vectors include alphavirus/retrovirus, 84 vaccinia/retrovirus, 85, 86 and herpes simplex virus/retrovirus combinations. 87 Despite these advances, hybrid production systems are still in early development battling issues of low titer and vector instability.
Several different methods for vector production, vector purification, and RCR tests are being explored
Vector production
The use of high-density perfusion systems is currently the best choice for high titer vector production since it allows continuous vector harvest, avoids concentration of toxic products, and high cell densities favor increased production rates (reviewed in Merten 88 ). Replacement of glucose by fructose achieved a five-to six-fold reduction in toxic lactate production in most media while titers increased 3-8 times (reviewed in Merten 88 ). The major drawbacks for retroviral vector production are relatively low titers and a short half-life of 2-9 h, which generally increases with decreasing production temperatures. 89, 90 Vector harvest in discontinuous production systems should occur at least every 24 h, 91 with every 8 h as the optimal harvest frequency to avoid vector decay. 90 Furthermore, vector stability correlates inversely with levels of producer cell-derived cholesterol in the viral lipid shell. 92 Important parameters influencing large-scale vector production are the choice of the producer cell line, media, and type of vessel for cell cultures. Advantages of reactors (stirred tank, fixed or packed bed, fluidized bed, hollow fiber) over multiple process systems (T-flasks, roller bottles, cell factories) include scalability, use of the perfusion method, and access to control units allowing close monitoring of culture conditions. Although few comparative studies for retroviral vector production in reactors have been published, best results so far are achieved in reactors that allow high cell densities. A comparison of stationary with different microcarrier cultures (Cytodex) showed that titers from solid microcarrier cultures were highest. 93 Similarly, Warnock et al 94 achieved a titer of 1 Â 10 7 TU/ml using Cytoline 1 microcarriers for fluidized-bed bioreactors compared to 5 Â 10 6 TU/ml in roller bottles.
Vector purification
Although most retroviral vector preclinical studies use concentrated crude vector, vector purification to remove contaminating DNA and foreign serum-and producer line-derived proteins is a must for clinical applications. Several groups demonstrated that purification not only ensures vector safety but significantly improves in vivo efficacy. 91, [95] [96] [97] Although retroviral vectors are only weakly immunogenic, vector contaminants can trigger local inflammatory responses and influence the onset of antivector particle immune responses. Scherr et al 97 purified lentiviral vectors with anion exchange columns, and Yamada et al 96 reported improved gene transfer with the first HPLC-purified lentiviral vectors. However, HPLC technology and centrifugation are not feasible for large vector supernatant volumes (B200 l). Hence, ultrafiltration has typically served to reduce volume prior to anion exchange or size exclusion column chromatography (SEC). An alternative procedure is the recently described Mustang Q ion exchange capsule, capable of purifying vector from large volumes (up to 1500 l/day) without prior concentration. 91, 98 Another issue is the removal of genomic and plasmid DNA from producer cells and transient vector production, respectively. Efficient DNA digestion with benzonase has been described 99 and conditions were further optimized by Sastry et al, 100 who suggested that DNA digest may not be necessary for ex vivo protocols since only minimal transfer of plasmid DNA to transduced cells has been detected. A typical large-scale retroviral vector purification protocol starts with a clarification step to separate vector-containing supernatant from cell debris, followed by concentration of vector material, benzonase digest, SEC or anion exchange chromatography, diafiltration, and final sterile filtration.
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RCR testing
Primary biosafety concerns for retroviral vectors are the presence of RCR and insertional mutagenesis. While RCR assays for MuLV vectors are well established, development of assays testing for lentiviral vectors (RCL) is complicated by the unknown nature of such a virus. In the absence of overlapping sequences between lentiviral vector components, only theoretical and unlikely recombinations between vector components alone (lentivirus and pseudotyping envelope virus) or between vector components and endogenous retroviral sequences of the producer cells might yield RCLs. For these reasons, it is difficult to predict an RCL's genomic organization and this makes RCL assays challenging since they have to be based on assumptions about the RCL's structure. Nevertheless, latest efforts to develop RCL assays include PCR-based protocols such as the sensitive product-enhanced reverse transcriptase (PERT) assay. 102 The conventional PERT assay is based on a two-step RT-PCR amplification of phage RNA relying on the reverse transcriptase associated with retroviral particles. Thus, PERT should permit detection of all infectious retroviruses irrespective of their origin or pseudotyping envelope. PERT has been further developed into a single tube assay with increased reproducibility while maintaining sensitivity (o10 virions). 69 Assays that detect VSV-G sequences and recombination between gag and the transfer vector using standard or quantitative PCR have been described, 103, 104 and RCL detection by p24 ELISA, although not the most sensitive method, can detect as little as one RCL in a background of 2.5 Â 10 8 TU. 105 One difficulty is the availability of a suitable positive control virus. To that end, Segall et al 106 proposed to use an artificially generated RCL and Schonely et al 104 used an attenuated HIV clone. To date, no RCL has been associated with lentiviral vectors although low level recombination between gag and the transfer vector results in transfer of Gag to target cells. 103 
Retroviral vector titering
Titering of retroviral vectors is still plagued by large intra-and interassay variation as well as differences between laboratories and operators. Hence, the development of novel titering methods continues such as total particle quantification using HPLC described by Transfiguracion et al, 107 and determination of infectious retrovirus titers from colony-forming assays applying quantitative analysis. 108 Titering comparison on the level of DNA, RNA and marker expression revealed that vector RNA titers in supernatants were 1000-fold higher than DNA titers from transduced cells, which in turn were 10-fold higher than marker expression-based titers. 109 In summary, titer reporting will benefit greatly from a generally available retrovirus reference material as previously described for adenoviral vectors. gag/pol, rev, tat and VSV-G. Safety features of this twoplasmid vector system include a ribozyme to prevent read-through from gag/pol into VSV-G sequences, and partially degenerate gag, rev and tat sequences to reduce homology to wild-type HIV. 77 In vitro studies with VRX496 achieved highly efficient gene transfer in 499% of CD4+ T lymphocytes, HIV replication was inhibited more than 1000-fold, with no significant in vivo vector mobilization detected. 77, 112 Furthermore, VRX496-induced mutations of wild-type HIV virus did not lead to escape mutants but rather severely attenuated HIV clones. 111 VRX496 was generated by a CaPO 4 -mediated transient production system using 10-layer cell factories and purification included a benzonase digest followed by SEC and release testing. 
Speculation/conclusion
Integrating vectors based on retro-and lentiviral genomes will continue to play an important role as gene transfer reagents. While these vectors offer advantages of long-term expression, low toxicity, high capacity and low antivector immunity allowing repeat administration, safety issues related to the integrating nature of these vectors caused some serious adverse events in the X-SCID trial using MLV-based vectors. A better understanding of integration site preferences within the family of retroviruses, coupled with improvements in vector design for increased biosafety, and progress towards controlled integration are favorable developments and should reduce the likelihood of insertional mutagenesis. Nevertheless, the first clinical trial with a lentiviral vector is encouraging and may signal the advent of the lentiviral vector era for clinical applications. Further developments in large scale manufacture and quality testing are critical and will support these efforts.
